The second PMT-related hub, GSK3β, was found to be less susceptible to STLs: it was reported that only DMAMCL and dihydroartemisinin effectively inhibited the expression and phosphorylation of β-catenin, a downstream effector of GSK3β, in glioblastoma cells [65,79]. This evidence concerns the gene GSK3B and glioblastoma.